All In Biotech

Drug Trial Radar · NCT06835361

Efficacy and Safety of Clotrimazole+Lactulose Vaginal Suppositories Vs. Clotrimazole Monotherapy in Adult Women with Candidal Vaginitis/Vulvovaginitis

International Open-label Randomized Comparative Clinical Study of Efficacy and Safety of Clotrimazole+Lactulose, Vaginal Suppositories (AVVA RUS JSC, Russia) Vs. a Clotrimazole Monocomponent Product in Adult Female Patients with Candidal Vaginitis/vulvovaginitis

Last checked: Nov 20, 2026Latest source record: Feb 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 264 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

264

Planned (sponsor's estimate)

Start

Feb 29, 2024

Primary completion

Sep 30, 2025

Study completion Nov 30, 2025

Sponsor

Lead sponsor
AVVA Pharmaceuticals Ltd.Industry
Sponsor type
Industry
First posted
Feb 19, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to compare the efficacy and safety of the combination drug Clotrimazole+Lactulose with the monocomponent product Canesten® (clotrimazole) in adult women diagnosed with candidal vulvovaginitis. The primary objective was to confirm the superiority of the combination drug in terms of clinical and microbiological response on Day 25 of the study.

Conditions

  • Candidal Vulvovaginitis (ICD-10 Code: B37.3)
  • Vulvovaginal Candidiasis (VVC)

Interventions

  • Clotrimazole+Lactulose.Drug

    Vaginal suppositories containing clotrimazole (100 mg) and lactulose (300 mg)

  • Canesten (Clotrimazole)Drug

    Vaginal tablets containing clotrimazole (100 mg)

  • LactuloseDrug

    Vaginal suppositories containing lactulose (300 mg)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion (%) of patients with clinical and microbiological response (recovery)Time frame: Day 25 (Visit 4)

Locations

7 sites in 2 countries. Site status is shown where the registry gives one.

  • Healthcare Institution "14th Central District Polyclinic of the Partizansky District of Minsk"

    Minsk, Belarus · Recruiting

  • Healthcare Institution "2nd Central District Polyclinic of the Frunzensky District of Minsk"

    Minsk, Belarus · Recruiting

  • Healthcare Institution "4th City Polyclinic" of Minsk

    Minsk, Belarus · Recruiting

  • Healthcare Institution "5th City Clinical Polyclinic" of Minsk

    Minsk, Belarus · Recruiting

  • State Institution "Republican Center of Medical Rehabilitation and Balneotherapy"

    Minsk, Belarus · Recruiting

  • Healthcare Institution "1st Central District Polyclinic of the Central District of Minsk"

    Minsk, Minsk City, Belarus · Recruiting

  • SBI RR "Regional Clinical Skin and Venereal Dispensary"

    Ryazan, Ryazan Oblast, Russia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.